- At present, there is no specific active substance against hepatitis E. As the disease kills 70,000 people every year, researchers are actively searching for one. The team from the Department of Molecular …
- At present, there is no specific active substance against hepatitis E. As the disease kills 70,000 people every year, researchers are actively searching for one. The team from the Department of Molecular and Medical Virology at Ruhr University Bochum, Germany, may have found what they’re looking for. The researchers showed that the compound K11777 prevents […]
- PDF | Hepatitis E virus (HEV) is a foodborne virus transmitted through the faecal–oral route that causes viral hepatitis in humans worldwide. Ever since… | Find, read and cite all the research you need on ResearchGate
- A center in Córdoba is leading a European study to determine the incidence of the disease, transmitted by rodents and the first diagnosis of which occurred in 2018 in Hong Kong
- Roche launches automated serology hepatitis E virus tests
- More than 2,000 cases of Hepatitis E have been recorded and seven people have died – now a public health emergency operations centre has been set up in response to the crisis
- A team of researchers from Korea University College of Medicine, including Professor Jin-Won Song from the Department of Microbiology, Professor Ji Hoon Kim from the Department of Internal Medicine, and …
- Hepatitis E virus (HEV), an emerging zoonotic pathogen, poses a significant public health concern worldwide. Recently, rat HEV (Rocahepevirus ratti genotype C1; HEV-C1) has been reported to cause zoonotic infections and hepatitis in humans. Human infections with HEV-C1 are considered to be underestimated worldwide due to limited knowledge of transmission routes, genome epidemiology, and the risk […]
- Viral hepatitis affects millions worldwide. Learn about the causes and risk factors for hepatitis A, B, C, D, and E and how to lower your risk.
- This study monitored viral load in asymptomatic blood donors, unveiling insights into the progression of HEV infections, vital for public health strategies.
- A combination therapy with multiple drugs is more effective than just one active compound. To begin with, at least.
- –
- 1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at the 8.5-year mark in Qindong. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide. Currently, two recombinant HEV vaccines exist; however, little is known
- Hepatitis B, which is an infection of the liver, affects more than one lakh people in India every year.
- A single mutation stands in the way of a drug's effectiveness. Understanding it helps find new therapeutic approaches.
- There are 5 types of viral hepatitis—A, B, C, D, and E—each caused by a different virus and contracted and prevented in different ways.
- Danjuma Adda on WHO's efforts against Hepatitis B and his call for global vaccination and treatment efforts.
- 1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at the 8.5-year mark in…
- 1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at the 8.5-year mark in Qindong. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide. Currently, two recombinant HEV vaccines exist; however, little is known
- Susan Hafenstein, PhD, Professor and CryoEM Director at The Hormel Institute, University of Minnesota, is the recipient of a six-month, $85,000 grant from Nationwide Children’s Hospital (National Institutes of Health). This support will enable the Hafenstein lab to use cryo-electron microscopy (cryoEM) and tomography (cryoET) to study the structure and functions of the hepatitis E […]